461 related articles for article (PubMed ID: 7544833)
1. Tumor antigen-specific immunization of bone marrow transplantation donors as adoptive therapy against established tumor.
Hornung RL; Longo DL; Bowersox OC; Kwak LW
J Natl Cancer Inst; 1995 Sep; 87(17):1289-96. PubMed ID: 7544833
[TBL] [Abstract][Full Text] [Related]
2. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor.
Makki A; Weidt G; Blachere NE; Lefrançois L; Srivastava PK
Cancer Immun; 2002 Apr; 2():4. PubMed ID: 12747749
[TBL] [Abstract][Full Text] [Related]
3. Induction of antitumor immunity using bone marrow-generated dendritic cells.
Porgador A; Snyder D; Gilboa E
J Immunol; 1996 Apr; 156(8):2918-26. PubMed ID: 8609412
[TBL] [Abstract][Full Text] [Related]
4. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L
Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169
[TBL] [Abstract][Full Text] [Related]
5. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
[TBL] [Abstract][Full Text] [Related]
6. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
7. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
[TBL] [Abstract][Full Text] [Related]
8. Induction of a CD8+ cytotoxic T lymphocyte response to soluble antigen given together with a novel muramyl dipeptide adjuvant, N-acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine (GMDP).
Hornung RL; Longo DL; Gowda VL; Kwak LW
Ther Immunol; 1995 Feb; 2(1):7-14. PubMed ID: 7553072
[TBL] [Abstract][Full Text] [Related]
9. Donor leukocyte infusion from immunized donors increases tumor vaccine efficacy after allogeneic bone marrow transplantation.
Teshima T; Liu C; Lowler KP; Dranoff G; Ferrara JL
Cancer Res; 2002 Feb; 62(3):796-800. PubMed ID: 11830535
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment.
Bathe OF; Dalyot-Herman N; Malek TR
BMC Cancer; 2003 Jul; 3():21. PubMed ID: 12882650
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic anti-tumor response induced with epitope-pulsed fibroblasts genetically engineered for B7.1 expression and IFN-gamma secretion.
Kim TS; Chung SW; Kim SH; Kang SN; Kang BY
Int J Cancer; 2000 Aug; 87(3):427-33. PubMed ID: 10897050
[TBL] [Abstract][Full Text] [Related]
12. Transfer of antigen-encoding bone marrow under immune-preserving conditions deletes mature antigen-specific B cells in recipients and inhibits antigen-specific antibody production.
Brooks JF; Barber JEM; Davies JM; Wells JW; Steptoe RJ
Cytotherapy; 2020 Aug; 22(8):436-444. PubMed ID: 32546362
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
14. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
[TBL] [Abstract][Full Text] [Related]
15. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: a strategy for using autologous marrow as an anti-tumor therapy.
Kwak LW; Campbell MJ; Zelenetz AD; Levy R
Blood; 1991 Nov; 78(10):2768-72. PubMed ID: 1824269
[TBL] [Abstract][Full Text] [Related]
16. Active immunization of murine allogeneic bone marrow transplant donors with B-cell tumor-derived idiotype: a strategy for enhancing the specific antitumor effect of marrow grafts.
Kwak LW; Pennington R; Longo DL
Blood; 1996 Apr; 87(7):3053-60. PubMed ID: 8639929
[TBL] [Abstract][Full Text] [Related]
17. Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study.
Zhou F; Rouse BT; Huang L
Cancer Res; 1992 Nov; 52(22):6287-91. PubMed ID: 1384958
[TBL] [Abstract][Full Text] [Related]
18. Effective adoptive transfer of haploidentical tumor-specific T cells in B16-melanoma bearing mice.
Cui NP; Xie SJ; Han JS; Ma ZF; Chen BP; Cai JH
Chin Med J (Engl); 2012 Mar; 125(5):794-800. PubMed ID: 22490577
[TBL] [Abstract][Full Text] [Related]
19. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow-derived T lymphocytes responsible for allograft rejection.
Senjanović M; Marusić M
Cell Immunol; 1984 Aug; 87(1):225-30. PubMed ID: 6204774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
